Movement Alert｜ImmunityBio, Inc. Rises 5.6% in Regular Trading, Anktiva Middle East approvals and commercialization progress support sentiment

Market Focus10-15

On October 15, ImmunityBio, Inc. rose 5.6% in Regular Trading, trading at $10.43 per share, with turnover of $63.8962 million.

The move was supported by continued market attention on commercialization progress for the company’s core product Anktiva in the Middle East.

Previously disclosed developments show Anktiva received marketing authorization in the UAE in July for certain bladder cancer and metastatic non-small cell lung cancer indications, after earlier reaching the Saudi market. The company also reported second-quarter revenue of $51.2 million, up from $26.4 million a year earlier and above expectations, indicating ongoing product ramp-up and overseas expansion, even as quarterly losses remained elevated.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment